EIi Lilly has announced plans to partner up with China’s National Center for Cardiovascular Diseases (NCCD), the nation’s institution responsible for the development of programmes to combat the prominent health threat, in order to promote better scientific understanding and patient care for those affected by type 2 diabetes and cardiovascular disorders (CVD).
Reageer